MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. The Company’s drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib has completed a Phase I trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) in combination with the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (marketed as Venclexta). Voruciclib is also being evaluated in pre-clinical studies to explore potential activity in various solid tumor cancers including in combination with therapies that target the RAS signaling pathway, such as KRAS inhibitors. MEI-344 is a drug candidate that inhibits mitochondrial OXPHOS, a fundamental metabolic pathway involved in the production of adenosine triphosphate (ATP) in the mitochondria.

• Revenue in USD (TTM)65.30m
• Net income in USD17.78m
• Incorporated2000
• Employees28.00

• Location
  MEI Pharma Inc11455 El Camino Real, Suite 250SAN DIEGO 92130United StatesUSA
• Phone+1 (858) 369-7100
• Fax+1 (302) 655-5049
• Websitehttps://www.meipharma.com/